Please assess the completion status of the following clinical trial:

Trial Title: Management of Participants With Low-level Persistent Viremia (ANRS 161 L-VIR)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years~* HIV-1 infection~* On combined antiretroviral regimen for at least 18 months~* Participant with a stable antiretroviral regimen for at least 6 months, including 2 Reverse-transcriptase inhibitor (INTI) + 1 Boosted Protease Inhibitor IP/r ,~* participant with at least 2 consecutive viral load between 50 and 500 copies/milliliter over the last 9 months (with at least 2 months between the two measurements) quantified with the same commercial kit.~* 50 \<or= VL \< 500 copies/milliliter at screening visit quantified with the same commercial kit than previous one.~* Participant naïve to raltegravir (RAL)~* failure of amplification or successful realization of genotypic resistance test without evidence for resistance mutations against current treatment (3TC/FTC accepted with M184V mutation)~* creatinin \< 3 Upper Limit normal (ULN)~* Aspartate Amino Transférase (ASAT), Alanine Amino Transférase (ALAT) \< 5 Upper Limit normal (ULN)~* hemoglobin \> 8 g/dL~* platelets \> 50 000/mm3~* In women, lack of current pregnancy verified by Beta Human Chorionic Gonadotropin (βHCG) at week -4 visit and use of a mechanical contraceptive method~* Informed consent~* Participants with an active health insurance coverage (article L1121-11 du Code de la Santé Publique)~Exclusion Criteria:~* HIV-2 infection,~* severe medical condition in the last month (inclusion is possible for a stable condition at screening)~* breastfeeding women, current pregnancy or planned pregnancy within 12 months.~* participant currently receiving Prezista® (darunavir)/ Norvir® (ritonavir) (600/100 mg) two times a day (BID) (of note, participants receiving Prezista® (darunavir)/ Norvir® (ritonavir) one time a day (QD) can be included)~* Hypersensitivity Prezista® (darunavir)/ Norvir® (ritonavir) or to any of the excipients of the study treatment~* participant under judicial protection (judicial protection due to temporarily and slightly diminished mental or physical faculties), or under legal guardianship~* planned absence that could prevent the patient from participating in the trial (travel abroad, moving, pending work transfer ...)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Counseling arm (Type: OTHER): Counseling without antiretroviral treatment modification
- Switch arm for protease inhibitor (Type: ACTIVE_COMPARATOR): Switch arm for protease inhibitor : intervention is the switch of current boosted protease inhibitor for Prezista® (darunavir)/ Norvir® (ritonavir) (switch for a drug with a higher genetic barrier) 600/100 mg two times a day (BID) with counseling.
- Addition of Isentress® (raltegravir) (Type: ACTIVE_COMPARATOR): Drug: Addition of Isentress® (raltegravir) arm~• Addition of Isentress® (raltegravir) arm :Isentress® (raltegravir) 400 mg two times a day (BID) added to current antiretroviral treatment with counseling

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues